TY  - JOUR
TI  - Helicobacter pylori treatment in Turkey: Current status and rational treatment options
AB  - According to the TURHEP study, the prevalence of Helicobacter pylori in Turkey is 82.5%. After FDA approval in 1995, manycountries have used standard triple therapy (proton pump inhibitor 40 mg b.i.d clarithromycin 500 mg b.i.d and amoxicillin 1gr b.i.d) for Helicobacter pylori treatment. In the beginning, eradication rates were above 90% in many countries; however,current studies have demonstrated a prominent decrease in successful treatment rates, even down to 60%. This unfavorable reduction stimulated searches for new treatment protocols. Treatment protocols differ according to country, prevalence,cost-effectiveness, antibiotic resistance, CYP2C19 polymorphism and eradication rates. Thus, each country/region needs torevise its own therapeutic results and the efficacy of various eradication regimens in the treatment of Helicobacter pylori.This report aims to review the current status of Helicobacter pylori treatment in Turkey and to provide recommendations forrational therapeutic considerations for the eradication of the bacterium.
AU  - TOZUN, Ayşe Nurdan
AU  - KAPLAN, Mustafa
AU  - DÜZENLİ, Tolga
AU  - TANOĞLU, Alpaslan
DO  - 10.14744/nci.2019.62558
PY  - 2020
JO  - İstanbul Kuzey Klinikleri
VL  - 7
IS  - 1
SN  - 2148-4902
SP  - 87
EP  - 94
DB  - TRDizin
UR  - http://search/yayin/detay/357578
ER  -